hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research[1].
References
[1] Feng M, et al. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells. Sci Adv. 2019 May 8;5(5):eaau5240. DOI:10.1126/sciadv.aau5240